6ei4: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
Line 1: | Line 1: | ||
==Crystal Structure of tyrosinase from Bacillus megaterium with B5N inhibitor in the active site== | |||
<StructureSection load='6ei4' size='340' side='right' caption='[[6ei4]], [[Resolution|resolution]] 2.00Å' scene=''> | |||
== Structural highlights == | |||
<table><tr><td colspan='2'>[[6ei4]] is a 2 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6EI4 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6EI4 FirstGlance]. <br> | |||
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=B5N:[4-[(4-fluorophenyl)methyl]piperazin-1-yl]-(2-methylphenyl)methanone'>B5N</scene>, <scene name='pdbligand=CU:COPPER+(II)+ION'>CU</scene></td></tr> | |||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6ei4 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6ei4 OCA], [http://pdbe.org/6ei4 PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6ei4 RCSB], [http://www.ebi.ac.uk/pdbsum/6ei4 PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6ei4 ProSAT]</span></td></tr> | |||
</table> | |||
<div style="background-color:#fffaf0;"> | |||
== Publication Abstract from PubMed == | |||
The inhibition of tyrosinase (Ty, EC 1.14.18.1) represents an efficient strategy of decreasing melanogenesis and skin hyperpigmentation. A combination of crystallographic and docking studies on two different tyrosinases, that from Bacillus megaterium (TyBm) and that from a mushroom (TyM), has contributed to increasing our knowledge about their structural information and translating that information to the most druggable human Ty (TyH) isozyme. In particular, we designed and synthesized a series of 1-(4-fluorobenzyl)piperazine and 1-(4-fluorobenzyl)piperidine derivatives showing inhibitory activities on TyM at micromolar ranges and more potency than that of the reference compound, kojic acid. The crystal structures of TyBm with inhibitor 3 (IC50 value of 25.11 muM) and 16 (IC50 value of 5.25 muM) were solved, confirming the binding poses hypothesized by in silico studies and revealing the main molecular determinants for the binding recognition of the inhibitors. | |||
Targeting Tyrosinase: Development and Structural Insights of Novel Inhibitors Bearing Arylpiperidine and Arylpiperazine Fragments.,Ferro S, Deri B, Germano MP, Gitto R, Ielo L, Buemi MR, Certo G, Vittorio S, Rapisarda A, Pazy Y, Fishman A, De Luca L J Med Chem. 2018 Apr 20. doi: 10.1021/acs.jmedchem.7b01745. PMID:29634898<ref>PMID:29634898</ref> | |||
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | |||
[[Category: | </div> | ||
<div class="pdbe-citations 6ei4" style="background-color:#fffaf0;"></div> | |||
== References == | |||
<references/> | |||
__TOC__ | |||
</StructureSection> | |||
[[Category: Benhar, Y Pazy]] | |||
[[Category: Deri, B]] | |||
[[Category: Fishman, A]] | |||
[[Category: Gitto, R]] | |||
[[Category: Inhibitor]] | |||
[[Category: Ligand]] | |||
[[Category: Oxidoreductase]] | |||
[[Category: Tyrosinase]] |